Inflammation Control Protocol

Overview

Chronic low-grade inflammation is implicated in nearly every major chronic disease — cardiovascular disease, insulin resistance, neurodegeneration, and autoimmune conditions. Unlike acute inflammation, which is protective, chronic inflammation reflects a failure of resolution, not merely excess stimulus. Effective interventions therefore target both upstream drivers (infection, dysbiosis, diet, adiposity, stress) and downstream resolution pathways.

This protocol combines three peptides with complementary anti-inflammatory profiles. KPV is the C-terminal tripeptide of alpha-MSH with potent mucosal and systemic anti-inflammatory action. BPC-157 is protective across multiple tissues and has anti-inflammatory effects particularly in the gut and soft tissue. LL-37 is a host defense peptide with immunomodulatory properties — used judiciously since it has immune-activating as well as anti-inflammatory roles depending on context.

Compounds Involved

KPV

KPV is notable for mucosal anti-inflammatory effects and has been investigated in models of inflammatory bowel disease and skin inflammation. Oral administration can deliver active compound to the GI tract directly.

BPC-157

BPC-157 exerts anti-inflammatory effects particularly in gut and soft tissue, and its broader systemic effects include vascular protection and nitric oxide system modulation.

LL-37

LL-37 is a double-edged tool; it has anti-inflammatory effects in some contexts and pro-inflammatory / immune-activating effects in others. Use is conservative and typically embedded in an immune modulation rather than pure inflammation-suppression strategy.

Protocol Structure

Phase 1 — Identify and Address Root Drivers (Weeks 1–4)

Chronic inflammation rarely has a single cause. This phase is the most important and the most commonly skipped.

• Workup — hs-CRP, ESR, ferritin, homocysteine, HbA1c, lipid panel, vitamin D, TSH; food sensitivity and gut testing selectively
• Dietary clean-up — emphasize whole foods, adequate fiber, EPA/DHA-rich fish 2–3x/week, remove refined seed oils and ultra-processed foods
• Weight / adipose reduction — adiposity is a major inflammatory driver; see Weight Loss Acceleration if BMI >30
• Sleep 8+ hours, consistent schedule
• Stress management — daily practice of breath work, meditation, or equivalent
• Omega-3 2 g EPA+DHA/day; Curcumin 500 mg with food

Phase 2 — Peptide Layer (Weeks 5–16)

• KPV 500 mcg/day — oral for GI-dominant inflammation, subcutaneous for systemic
• BPC-157 250 mcg subcutaneous daily, or 500 mcg oral if targeting gut
• LL-37 100 mcg subcutaneous 2x/week — reserved for cases where immune under-activation (e.g. chronic biofilm, stealth infection) is suspected
• Continue all Phase 1 interventions

Phase 3 — Reassessment and Taper (Week 16)

• Repeat inflammatory markers and relevant labs
• Taper peptides: LL-37 first, then BPC-157, then KPV
• Continue omega-3, curcumin, and lifestyle interventions indefinitely

Cycling

Peptide components are typically run in 12–16 week blocks followed by 4–8 weeks off. Foundational lifestyle and dietary interventions run continuously.

Important Considerations

• Screen for treatable underlying causes of chronic inflammation before assuming it is idiopathic. Dental infection, H. pylori, periodontal disease, chronic sinusitis, and sleep apnea are commonly overlooked.
• LL-37 is not appropriate for individuals with psoriasis or rosacea, where elevated LL-37 is part of the disease process.
• Anti-inflammatory tools that are too aggressive can blunt training adaptations and slow healing of acute injuries. Chronic suppression is not the goal — resolution is.
• Individuals on immunosuppressive medications or with known autoimmune disease should coordinate with a specialist; see Autoimmune Support Protocol.
• BPC-157 and KPV are generally well tolerated but infrequent skin reactions at injection sites do occur.
• Curcumin can interact with anticoagulants (increased bleeding risk) and may raise liver enzymes transiently.
• Persistently elevated hs-CRP (>3 mg/L) without an identified cause warrants further cardiology and rheumatology evaluation.

Disclaimer

This content is for educational and informational purposes only and is not medical advice. KPV, BPC-157, and LL-37 are not FDA-approved for human use and are sold as research chemicals in most jurisdictions. Chronic inflammation may be a marker of serious underlying disease and requires proper medical evaluation. Consult a qualified clinician before beginning any peptide protocol. Pepperpedia does not endorse the acquisition or use of unapproved substances.